Taejoon Pharmaceutical Co., Ltd.
17
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
71%
12 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Role: lead
Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease
Role: collaborator
A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy
Role: lead
Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects
Role: lead
Chest CT Using Low-concentration Iodine Contrast Media
Role: collaborator
A Phase 3 Trial in Bowel Preparation for Colonoscopy
Role: lead
A Study on the Verification of Kidney CT Non-inferiority Using Low Concentration Contrast Agent
Role: collaborator
A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 Trial
Role: lead
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
Role: lead
Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients
Role: lead
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
Role: lead
Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
Role: lead
A Study of HCC High Risk Group Using Two Surveillance Tools
Role: collaborator
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
Role: lead
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Role: lead
A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for Colonoscopy
Role: lead
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
Role: lead
All 17 trials loaded